S

Sanofi

Global pharma company; vaccines and R&D

Therapeutic Specialist

Full-TimeUpdated on 10/23/2026Deadline 11/30/26
$125.3k - $208.8k
Mid
Bachelor's
Remote in USA
RemoteUS Remote; travel up to 80% to customers, conventions, training, and internal meetings.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • At least 3 years of pharmaceutical, biotech, or medical device sales experience is required.
  • Account management sales experience is required.
  • A valid driver's license is required.
  • Ability to travel up to 80% of the time to customers, conventions, training, and other internal meetings is required.
  • Candidates must complete all fleet safety training and maintain an acceptable driving record regarding accidents and incidents.
Responsibilities
  • Build awareness and intent to treat with endocrinologists.
  • Build belief in Tzield's mechanistic rationale and clinical narrative, including beta-cell preservation, approved indication, efficacy, and safety profile.
  • Develop in-depth knowledge of key accounts across the territory, including barriers to Tzield use.
  • Contribute to priority account strategy development led by SAMs and execute engagement with endocrinology and primary care providers on Tzield use.
  • Develop and execute growth-oriented account and business plans for non-priority endocrinology accounts, including account mapping and influence mapping.
  • Identify account champions and key opinion leaders, and engage them as appropriate to communicate with peers and patients about Tzield.
  • Build awareness of type 1 diabetes early detection and the importance of screening asymptomatic, undiagnosed populations.
  • Conduct territory-level strategic planning to understand and contribute to the broader type 1 diabetes ecosystem, prioritizing time, engagement, and education strategy.
  • Contribute to screening strategy development and execute engagement with primary care providers and pediatricians on early detection and screening.
  • Collaborate with stakeholders to identify and educate on the importance of urgent referrals for identified patients within a narrow treatment window.
  • Educate relevant stakeholders on at-risk populations, screening and monitoring best practices, and the value of early detection, including diabetic ketoacidosis avoidance.
  • Collaborate with cross-functional Sanofi teams to support customers.
  • Attend local, regional, and national meetings as directed.
  • Maintain strict adherence to legal, regulatory, ethical, administrative, and financial duties.
  • Achieve and exceed assigned monthly, quarterly, and annual sales quotas.
Desired Qualifications
  • Rare specialty product experience.
  • Ability to understand and use data to improve business management and oversight of sales within customer territories.
  • Proven results increasing educational awareness, provider adoption, and customer engagement.
  • Experience successfully launching products in the field.
  • Experience collaborating and working in a matrix environment across multiple sales, medical, and support functions.
  • Strong business acumen and a solution-oriented mindset.
  • Ability to strategically plan and execute work.
  • Ability to engage in two-way stakeholder dialogue.
  • High accountability for feedback, coaching, and results.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...